- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04163796
UPnRIDE Power Standing Wheelchair for SCI
Evaluation of an Upright Powered Wheelchair for People With SCI
People with higher level of spinal cord injury have limitations to using exoskeletal-assisted walking devices due to restrictions of trunk stability, functional use of the upper extremities and hand grip. With increasing sedentary time in wheelchairs, people with SCI have a high risk for developing secondary complications. A powered wheelchair has recently been developed for use in persons with spinal cord injury that provides a solution for placing the user in an upright, standing position while maintaining the overground mobility features of the powered wheelchair; providing the ability to engage in society in either a standing or seated position. The purpose of this study is to verify user performances of the upright powered wheelchair and to identify obstacles that are difficult, or prevent use. Additionally, the option to have upright posture throughout the day may have the potential to improve some of the secondary medical conditions associated with the extreme sedentary lifestyle.
This study will determine change from baseline after 12 weeks of use for safety, tolerance, medical, physical and quality of life outcomes. The intervention will consist of 3.5 hours per session, 3 times per week for 12 weeks. During each session, participants will be asked to stand at least 5 minutes during every 15 minutes. To our knowledge, there is no existing empirical data on intermittent standing during the day in persons with higher levels of SCI who cannot otherwise stand and whether this approach will improve health related outcomes.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Eunkyoung Hong, PhD
- Phone Number: 5426 718-584-9000
- Email: eunkyoung.hong@va.gov
Study Locations
-
-
New York
-
Bronx, New York, United States, 10468
- Spinal Cord Damage Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Power wheelchair user as a primary means of mobility;
- 18-89 years old;
- ≥1 year after SCI;
- Height of 160 to 190 cm;
- Weight of <100 kg; and
- Able to sign informed consent.
Exclusion Criteria:
- Able to ambulate with or without an assistive device or physical assistance greater than 4 consecutive steps;
- Any pressure ulcer at any body location that is deemed to be contraindicated for a power wheelchair or standing frame by the study physician;
- Concurrent medical disease that would be exclusionary for standing (as per the clinical judgment of the study physician);
- Severe spasticity (Ashworth 4) or uncontrolled clonus;
- History of fragility fractures, long bone fractures in the past 1 years, heterotrophic ossification, or other bone conditions that would be exclusionary for use of a standing modality as per the clinical judgment of the study physician;
- Significant contractures that would be exclusionary for use of a standing modality as per the clinical judgment of the study physician
- Psychiatric or cognitive status that may interfere with the ability to follow instruction to use the device; and
- Pregnant or lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UPnRIDE Training
During each session, heart rate (HR), blood pressure (BP), total session time, time in standing posture, count of sit-to-stand positioning, total distance of overground movement, and rating of perceived exertion (Borg scale) for mobility skills will be monitored.
At all study visits during the training period, participants will be asked to answer general health questions about the occurrence of any pressure ulcers or infections.
|
The intervention will consist of approximately 3.5 hours per session, 3 times per week over 12 weeks.
During each 3.5-hour session, subjects will be asked to stand at least 5 minutes during every 15 minutes or more as tolerated.
One time each session, participants will be asked to perform the Activities of Daily Living course.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wheelchair mobility skills - RPE
Time Frame: Training Period - 36 Sessions up to 12 weeks
|
Participants will be requested to perform a rating of perceived exertion (RPE).
|
Training Period - 36 Sessions up to 12 weeks
|
Wheelchair mobility skills - FIM
Time Frame: Training Period - 36 Sessions up to 12 weeks
|
Participants will be requested to perform a rating Functional Independence Measurement (FIM) for each UPnRIDE activity.
|
Training Period - 36 Sessions up to 12 weeks
|
Activities Daily Living Course - RPE
Time Frame: Training Period - 36 Sessions up to 12 weeks
|
Participants will be requested to perform a rating of perceived exertion (RPE) during the Activities Daily Living Course (ADLC).
|
Training Period - 36 Sessions up to 12 weeks
|
Activities Daily Living Course - FIM
Time Frame: Training Period - 36 Sessions up to 12 weeks
|
Participants will be requested to perform a rating Functional Independence Measurement (FIM) during the Activities Daily Living Course (ADLC).
|
Training Period - 36 Sessions up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postural orthostatic hypotension blood pressure tolerance test (OH BP)
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Participants will be in the supine position on a bed or elevated gym mat and beat-to-beat HR will be recorded for 60 seconds, followed by passive re-positioning to the seated position on a bed or elevated gym mat with the hip and knee at a 90° angle and the lower leg hanging off the side.
Passive repositioning will be accomplished by one staff member lifting the participant's torso by the shoulders, while supporting the head and neck, and a second staff member shifting the subject perpendicular to the bed and allowing the participant's legs to hang off the side.
Participants will be instructed not to assist in the passive movement during this transition, and will be supported by staff.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Pulmonary function tests - Spirometry
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
While seated in the chair and after a mouth piece and nose clip are applied, the subject will be asked to breathe normally for 3 to 6 breaths.
They will then be instructed to forcibly inhale until their lungs are filled.
After a brief pause, they will then be instructed to forcibly exhale the air in their lungs and hold the maneuver for approximately 6 seconds.
After a brief rest, the maneuver will be repeated a minimum of three times to ensure reliability.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Pulmonary function tests - Static Lung Volumes
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
The volume of air in the lungs will be assessed using the nitrogen washout technique.
The nitrogen washout technique, which takes about five minutes to perform, will begin while a subject is seated in his/her wheelchair and after a mouth piece and nose-clips have been applied.
The subject will then be asked to breathe room air into and out of the mouthpiece for 3-6 breaths.
The air exhaled, which normally contains mostly nitrogen, will be collected and analyzed by the pulmonary function cart.
Once a participant has completed the 3-6 breaths, s/he will be asked to take a slow deep breath in and to exhale until the lungs are empty, after which the participant returns to a normal breathing pattern.
Following an additional 3-6 regular breaths, the pulmonary function cart will begin delivering 100% oxygen through the mouthpiece.
The subject will continue to inhale 100% oxygen while taking normal breaths until oxygen is the only gas measurable in his/her exhaled air.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Pulmonary function tests - Breathing Pattern
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Resting breathing pattern will be measured by abdominal and thoracic respiratory inductive plethysmography.
The participant will be asked to wear two chest straps for a designated period of time.
Signals from the participant's chest wall excursions are analyzed for indices of resting breathing pattern such as tidal volume and timing and derivatives of these measurements.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Inflammatory biomarkers
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Due to its clinical utility and widespread use to measure risks for coronary heart disease, the primary outcome assessment of systemic inflammation will be levels of CRP, which will be measured in sera using a commercially available ELISA.
Additional exploratory analyses may be performed using commercially available single- and multi-plex immunoassays to assay the following: HMGb1, IL-1β, IL-1Ra, IL-6, IL-8, IL-10, IL-15, MIF, MIP1-α/CCL3, TNF-α, leptin, and adipokine.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Body Composition
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
A dual energy x-ray absorptiometry (DXA) scan for regional and total body fat, lean and bone tissue masses will be performed two times: at baseline and post.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Bowel function surveys - 10Q Bowel Function Survey (BFS)
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
The 10Q Bowel Function Survey (BFS) will be administered three times: at baseline, midpoint, and post.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Bowel function surveys - Bristol Stool Scale
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
The Bristol Stool Scale (BSS) will be administered three times: at baseline, midpoint, and post.
The BSS is a diagnostic medical tool designed to classify the form of human faces into seven categories (Type 1 to 7: Hard lumps to Soft/Liquid).
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
SCI-QOL
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
The Spinal Cord Injury Quality of Life measurement tool is the first validated SCI-specific QOL measurement tool for the field.
The specific short form item banks to be use are: Bowel and Bladder Management Difficulties from the Physical Medical Domain, Ability to Participate and Independence from the Social Domain, and Positive Affect, and Resilience from Emotional Domain.
These will be performed three times: at baseline, midpoint, and post.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Lipid Profile - Cholesterols
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), triglyceride (TG) and high density lipoprotein cholesterol (HDL-c) values will be measure and samples will be collected at baseline, midpoint and post.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Homeostatic Model of Insulin Resistance (HOMA-IR)
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
The standard equation for the HOMA-IR will be used to calculate insulin resistance [HOMA-IR = FPG (mg/dl) x FPI(μU/mL) / 405].
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Serum total testosterone levels
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Serum total testosterone will be determined by a radioimmunoassay (RIA; MP Biomedicals, Costa Mesa, CA) kit with an intra-assay CV of 10.0, 9.6, and 13% at 1.4, 4.6, and 8.0 nmol/L41,61,62.
Measurements will be performed pre, midpoint and post.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Serum estradiol levels
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Serum estradiol values will be determined by a commercial kit assay using RIA (MP Biomedicals, Costa Mesa, CA) with an intra-assay CV of 15.7, 5.5, and 3.5% at 25.4, 152, and 657 pg/mL63.
Measurements will be performed pre, midpoint and post.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Lower extremity blood flow
Time Frame: Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Lower extremity blood flow will be measured by strain gauge and will be assessed at sessions 1 and 36.
|
Evaluations - Baseline/After session 18 (up to 6 weeks) /After session 36 (up to 12 weeks)
|
Collaborators and Investigators
Investigators
- Principal Investigator: EunKyoung Hong, PhD, Bronx VMRF
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPU-17-036
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injuries
-
Khon Kaen UniversityUnknownInjuries, Spinal Cord
-
Universidade do Vale do ParaíbaCompletedInjuries, Spinal Cord
-
InVivo TherapeuticsTerminated
-
Ekso BionicsBurke Medical Research InstituteCompletedInjuries, Spinal CordUnited States
-
ReWalk Robotics, Inc.Unknown
-
Shepherd Center, Atlanta GACompletedInjuries, Spinal Cord
-
Wroclaw Medical UniversityInstitute of Immunology and Experimental Therapy of the Polish Academy of... and other collaboratorsUnknownComplete Spinal Cord InjuriesPoland
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Epidural Spinal Cord CompressionUnited States
Clinical Trials on UPnRIDE power wheelchair
-
UPnRIDE Robotics Ltd.Sheba Medical CenterUnknownSpinal Cord Injury CervicalIsrael
-
University of OklahomaU.S. Department of EducationCompletedCerebral Palsy | Child, PreschoolUnited States
-
Université Catholique de LouvainRecruitingCerebral Palsy | Neuromuscular DiseasesBelgium
-
Grand Valley State UniversityActive, not recruitingCerebral Palsy | Spinal Cord Injuries | Spinal Muscular Atrophy | Genetic Disease | Spina Bifida | Development DelayUnited States
-
Grand Valley State UniversityNot yet recruitingCerebral PalsyUnited States
-
VA Office of Research and DevelopmentCompletedBlindness | Spinal Cord InjuryUnited States
-
VA Office of Research and DevelopmentRecruiting
-
HaEmek Medical Center, IsraelCompletedFatigue | Back Pain | Personal SatisfactionIsrael
-
Guangzhou University of Traditional Chinese MedicineCompleted
-
Nova Scotia Health AuthorityDalhousie UniversityCompleted